

SWIXX AND KYOWA KIRIN EXPAND PARTNERSHIP FOR RARE DISEASE PORTFOLIO TO 13 COUNTRIES IN EUROPE

SWIXX ANNOUNCEMENT NO. 49

December 19, 2022

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of two additional Promotion and Distribution Agreements with Kyowa Kirin Services, Ltd. and Kyowa Kirin Holdings B.V., both of which are wholly-owned subsidiaries of Kyowa Kirin Co., Ltd. of Tokyo, Japan.

On October 10th of this year, Kyowa Kirin and Swixx announced a partnership to exclusively market, promote and distribute CRYSViTA[®] (burosumab) and POTELIGEO[®] (mogamulizumab) in Poland (Swixx Announcement No. 48).

The two new agreements announced today expand that partnership to thirteen additional countries. In the first agreement, Kyowa Kirin has appointed Swixx to exclusively market, promote and distribute the two medicines in seven European Union (EU) countries; Bulgaria, Croatia, Czech Republic, Hungary, Romania, Slovakia and Slovenia. The second agreement has appointed Swixx to market, promote and distribute the same medicines within six West Balkan countries; Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.

“We are honored that Kyowa Kirin chose to extend its partnership with Swixx to another 13 countries in Europe,” said Dr. Dezso Martha, Swixx’s COO. “Kyowa Kirin has built up an excellent CEE network in the last few years as it launched its rare disease portfolio. I am confident,” Martha continued, “that by working with Kyowa Kirin and harnessing the momentum of these two medicines across the region, we will be able to improve access to Kyowa Kirin’s innovative portfolio as quickly as possible for those patients who need them.”

Dr. Laur Saar, Medical, Regulatory and Pharmacovigilance Director at Swixx outlined, “We are very pleased to extend our support for burosumab and mogamulizumab to thirteen additional countries, with Swixx now covering all of CEE. Both of these orphan medicines have the potential to address the significant unmet needs of patients, and we are confident that by providing medical support in extending treatment options, we can improve patient outcomes across our countries. We are committed to working closely together with Kyowa Kirin to best serve our patients.”

“Kyowa Kirin has a rich heritage of developing strong partnerships to help achieve our core purpose, to make people smile,” said Abdul Mullick, President of Kyowa Kirin International. “By extending our relationship with Swixx in this way we are living that purpose, leveraging both organisation’s expertise and infrastructure to continue delivering life-changing value to people living every day with CTCL, XLH and TIO across the region.”

About CRYSViTA® (burosumab) and POTELIGEO® (mogamulizab)

Burosumab is a recombinant human monoclonal (IgG1) antibody that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). Crysvida is indicated for the treatment of X-Linked Hypophosphataemia (XLH), in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. Crysvida is also indicated for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localized in children and adolescents aged 1 to 17 years and in adults.¹

Mogamulizab is a monoclonal antibody that selectively binds to CC chemokine receptor 4 (CCR4) and is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. Both MF and SS belong to a group of rare cancers of blood cells, cutaneous T-cell lymphomas (CTCLs), that affect mainly the skin.²

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: <https://www.kyowakirin.com/>.

Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Moldova and Uzbekistan. With over 1200 employees and sales likely to exceed 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma in CEE, Greece, CIS and Russia. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG

vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

References:

¹European Medicines Agency, Summary of product characteristics, Crysvida (burosumab). Available at: www.ema.europa.eu/en/documents/product-information/crysvida-epar-product-information_en.pdf. Last accessed: December 2022.

²European Medicines Agency, Summary of product characteristics, Poteligeo (Mogamulizab). Available at: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf. Last accessed: December 2022.